Table 2

Demographic, clinical and MRI characteristics of patients with CIS, RRMS and PMS

Demographic and clinical variablesCIS (n=61)RR (n=326)PMS (n=163)p Value
Females, n (%)45 (73.8)228 (69.9)117 (71.8)0.798
Age in years, mean (SD)38.1 (10.9)43.9 (10.6)54 (8.0)<0.0001
Age at onset, mean (SD) median36 (10.9)31.7 (9.2)33.3 (11.1)0.007
Expanded Disability Status Scale, median (range)1.5 (3.0)2.0 (5.5)6.0 (6.0)<0.0001
Disease duration in years, mean (SD)2.4 (2.7)12.1 (8.9)20.8 (11.0)<0.0001
Race, n (%)
 Caucasian54 (88.5)295 (90.5)154 (94.5)0.622
 African–American2 (3.3)15 (4.6)3 (1.8)
 Other5 (8.2)16 (4.9)6 (3.7)
Disease-modifying therapy, n (%)
No therapy30 (49.2)83 (25.5)49 (30)0.018
Interferon β-1a intramuscular19 (31.2)81 (26.1)37 (22.7)
 Glatiramer acetate0 (0)64 (20.6)34 (20.9)
 Natalizumab7 (11.5)54 (17.4)19 (11.7)
 Interferon β-1a subcutaneous4 (6.6)30 (9.2)10 (6.2)
 Combination therapy1 (1.7614 (3.9)14 (8.6)
MRI variables, mean (SD)
 T2-LN21.0 (24.2)27.2 (18.8)32.2 (21.1)0.001
 T2-LV3.8 (4.9)11.5 (14)18.7 (18.1)<0.0001
 T1-LN3.7 (7.2)10 (11.0)14.1 (12.6)<0.0001
 T1-LV0.4 (0.7)2.5 (5.7)4.3 (6.5)<0.0001
 NBPV1546.1 (62.6)1491.7 (90.2)1423.1 (80.8)<0.0001
 NGMV790.3 (49.9)744.3 (65.5)704.8 (57.3)<0.0001
 NWMV755.7 (40.9)747.4 (62.5)718.2 (69.8)<0.0001
 NLVV35.2 (13.4)45.7 (20.6)58 (23.5)<0.0001
  • Differences between groups were analysed by the χ2 test and analysis of variance. MRI differences between groups were analysed using the analysis of covariance, adjusted for age and sex. MRI volumes are expressed in millilitres.

  • BMI, body mass index; CIS, clinically isolated syndrome; LN, lesion number; LV, lesion volume; NBPV, normalised brain parenchymal volume; NGMV, normalised grey matter volume; NLVV, normalised lateral ventricle volume; NWMV, normalised white matter volume; PMS, progressive multiple sclerosis; RR, relapsing–remitting; RRMS, RR multiple sclerosis.